These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 1432610)

  • 41. Blood levels of reduced haloperidol versus clinical efficacy and extrapyramidal side effects of haloperidol.
    Lane HY; Lin HN; Hu OY; Chen CC; Jann MW; Chang WH
    Prog Neuropsychopharmacol Biol Psychiatry; 1997 Feb; 21(2):299-311. PubMed ID: 9061775
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Intensive treatment with haloperidol of treatment-resistant chronic schizophrenic patients.
    Hollister LE; Kim DY
    Am J Psychiatry; 1982 Nov; 139(11):1466-8. PubMed ID: 7137396
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Reduced haloperidol plasma concentration and clinical response in acute exacerbations of schizophrenia.
    Kelly MW; Perry PJ; Coryell WH; Miller DD; Arndt SV
    Psychopharmacology (Berl); 1990; 102(4):514-20. PubMed ID: 2096408
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Interaction between carbamazepine and bromperidol.
    Otani K; Ishida M; Yasui N; Kondo T; Mihara K; Suzuki A; Furukori H; Kaneko S; Inoue Y
    Eur J Clin Pharmacol; 1997; 52(3):219-22. PubMed ID: 9218929
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Haloperidol dosing requirements: the contribution of smoking and nonlinear pharmacokinetics.
    Perry PJ; Miller DD; Arndt SV; Smith DA; Holman TL
    J Clin Psychopharmacol; 1993 Feb; 13(1):46-51. PubMed ID: 8486817
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Haloperidol and reduced haloperidol serum levels: correlation with psychopathology in acute schizophrenia.
    Stevens A; Mahal A; Gaertner HJ
    Pharmacopsychiatry; 1992 Sep; 25(5):218-23. PubMed ID: 1409866
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Involvement of cytochromeP4503A4 in the metabolism of haloperidol and bromperidol].
    Furukori H
    Nihon Shinkei Seishin Yakurigaku Zasshi; 1998 Feb; 18(1):9-14. PubMed ID: 9592806
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Use of haloperidol in high doses in schizophrenia. Clinical, biochemical and pharmacokinetic study].
    Scatton B; Zarifian E; Bianchetti G; Cuche H; Loo H; Morselli PL
    Encephale; 1982; 8(1):1-8. PubMed ID: 7094868
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Reduced haloperidol/haloperidol ratios in plasma: polymorphism in Japanese psychiatric patients.
    Someya T; Takahashi S; Shibasaki M; Inaba T; Cheung SW; Tang SW
    Psychiatry Res; 1990 Feb; 31(2):111-20. PubMed ID: 2326392
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Correlation of haloperidol levels between saliva and plasma of acutely ill schizophrenic patients.
    Jain T; Bhandari A; Ram V; Sharma S; Parakh M; Parakh MC
    Clin Biochem; 2011 Jun; 44(8-9):675-80. PubMed ID: 21458435
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Dextromethorphan phenotyping and haloperidol disposition in schizophrenic patients.
    Lane HY; Hu OY; Jann MW; Deng HC; Lin HN; Chang WH
    Psychiatry Res; 1997 Mar; 69(2-3):105-11. PubMed ID: 9109178
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Human scalp hair as evidence of individual dosage history of haloperidol: method and retrospective study.
    Uematsu T; Sato R; Suzuki K; Yamaguchi S; Nakashima M
    Eur J Clin Pharmacol; 1989; 37(3):239-44. PubMed ID: 2612538
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pharmacokinetic protocol for predicting plasma haloperidol concentrations.
    Miller DD; Perry PJ; Kelly MW; Coryell WH; Arndt SV
    J Clin Psychopharmacol; 1990 Jun; 10(3):207-12. PubMed ID: 2376619
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Lower plasma levels of haloperidol in smoking than in nonsmoking schizophrenic patients.
    Shimoda K; Someya T; Morita S; Hirokane G; Noguchi T; Yokono A; Shibasaki M; Takahashi S
    Ther Drug Monit; 1999 Jun; 21(3):293-6. PubMed ID: 10365639
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Significant dose effect of carbamazepine on reduction of steady-state plasma concentration of haloperidol in schizophrenic patients.
    Yasui-Furukori N; Kondo T; Mihara K; Suzuki A; Inoue Y; Kaneko S
    J Clin Psychopharmacol; 2003 Oct; 23(5):435-40. PubMed ID: 14520118
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The assessment and clinical implications of haloperidol acute-dose, steady-state, and withdrawal pharmacokinetics.
    Khot V; DeVane CL; Korpi ER; Venable D; Bigelow LB; Wyatt RJ; Kirch DG
    J Clin Psychopharmacol; 1993 Apr; 13(2):120-7. PubMed ID: 8463444
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Intra- and interethnic variability in reduced haloperidol to haloperidol ratios.
    Lam YW; Jann MW; Chang WH; Yu HS; Lin SK; Chen H; Davis CM
    J Clin Pharmacol; 1995 Feb; 35(2):128-36. PubMed ID: 7751421
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Plasma alpha-one acid glycoprotein and haloperidol concentrations in schizophrenic patients.
    Jann MW; Crabtree BL; Pitts WM; Lam YW; Carter JG
    Neuropsychobiology; 1997; 36(1):32-6. PubMed ID: 9211442
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Quetiapine : A Review of its Use in Schizophrenia.
    Gunasekara NS; Spencer CM
    CNS Drugs; 1998 Apr; 9(4):325-40. PubMed ID: 27521016
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Comparison of haloperidol plasma concentrations between twice-a-day and once-a-day dosing in Chinese schizophrenic patients.
    Lin SK; Chen CH; Chang WH
    J Formos Med Assoc; 1993 Sep; 92(9):832-4. PubMed ID: 7904867
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.